1
Clinical Trials associated with Human immunoglobulin(pH4)(Xinjiang Deyuan Biological Engineering Co.,Ltd.)静注人免疫球蛋白(pH4)治疗原发免疫性血小板减少症随机、单盲、阳性药平行对照、多中心临床试验
[Translation] A randomized, single-blind, positive-drug parallel-controlled, multicenter clinical trial of intravenous human immunoglobulin (pH4) in the treatment of primary immune thrombocytopenia
以已上市静注人免疫球蛋白(pH4)为对照,评价新疆德源生物工程有限公司研制开发的静注人免疫球蛋白(pH4)治疗原发免疫性血小板减少症的有效性和安全性
[Translation] To evaluate the efficacy and safety of intravenous human immunoglobulin (pH4) developed by Xinjiang Deyuan Bioengineering Co., Ltd. in the treatment of primary immune thrombocytopenia, using the marketed intravenous human immunoglobulin (pH4) as a control.
100 Clinical Results associated with Human immunoglobulin(pH4)(Xinjiang Deyuan Biological Engineering Co.,Ltd.)
100 Translational Medicine associated with Human immunoglobulin(pH4)(Xinjiang Deyuan Biological Engineering Co.,Ltd.)
100 Patents (Medical) associated with Human immunoglobulin(pH4)(Xinjiang Deyuan Biological Engineering Co.,Ltd.)
1
Literatures (Medical) associated with Human immunoglobulin(pH4)(Xinjiang Deyuan Biological Engineering Co.,Ltd.)01 Jun 1990·Vox sanguinis
Transmission of Non‐A, Non‐B Hepatitis by pH4‐Treated Immunoglobulin
Letter
Author: H.-J. Heiniger ; J.-J. Morgenthaler
100 Deals associated with Human immunoglobulin(pH4)(Xinjiang Deyuan Biological Engineering Co.,Ltd.)